bioAffinity Technologies, Inc.
BIAF
$0.2872
-$0.0088-2.97%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 78.40% | 269.68% | 2,814.72% | 30,256.85% | 86,531.58% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 78.40% | 269.68% | 2,814.72% | 30,256.85% | 86,531.58% |
| Cost of Revenue | 74.34% | 243.70% | 7,887.14% | 294,943.75% | 662,740.00% |
| Gross Profit | 86.67% | 326.79% | 1,237.79% | 11,434.22% | 31,126.92% |
| SG&A Expenses | 30.42% | 46.43% | 60.31% | 105.27% | 134.55% |
| Depreciation & Amortization | 61.71% | 142.53% | 455.27% | 886.58% | 1,167.11% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 38.70% | 74.34% | 133.86% | 168.20% | 174.33% |
| Operating Income | -15.25% | -12.29% | -15.09% | -46.05% | -72.67% |
| Income Before Tax | -16.38% | -14.05% | -16.79% | 11.45% | -1.83% |
| Income Tax Expenses | 29.46% | -44.29% | -25.13% | -17.96% | 6.61% |
| Earnings from Continuing Operations | -16.40% | -13.89% | -16.68% | 11.46% | -1.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.40% | -13.89% | -16.68% | 11.46% | -1.84% |
| EBIT | -15.25% | -12.29% | -15.09% | -46.05% | -72.67% |
| EBITDA | -12.90% | -9.33% | -9.77% | -40.34% | -67.92% |
| EPS Basic | 22.69% | 17.51% | 5.83% | 48.68% | 41.93% |
| Normalized Basic EPS | 22.70% | 17.42% | 5.77% | 48.70% | 44.72% |
| EPS Diluted | 22.69% | 17.51% | 5.83% | 48.68% | 41.93% |
| Normalized Diluted EPS | 22.70% | 17.42% | 5.77% | 48.70% | 44.72% |
| Average Basic Shares Outstanding | 50.34% | 38.58% | 26.34% | 33.03% | 53.60% |
| Average Diluted Shares Outstanding | 50.34% | 38.58% | 26.34% | 33.03% | 53.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |